Cannabidiol (CBD) is the principal non-psychoactive component of the hemp plant. Unlike THC (delta-9 tetrahydrocannabinol), CBD doesn’t give users a psychotropic high. Its strength lies elsewhere. Over the past few years, the compound has helped people deal with a variety of medical conditions, ranging from insomnia and menstrual cramps to chronic pain and epilepsy.
While there’s plenty of anecdotal evidence, there has been very little scientific research on CBD’s effectiveness and side effects, and a lot of people are cynical about its abilities. Despite this, demand for CBD products is growing at…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor